Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction (Nerve-RESTORE℠)

15. Juni 2026 aktualisiert von: Axogen Corporation
This is a multicenter, 1:1 randomized, prospective, comparative study in participants requiring reconstruction of a mixed or motor nerve in the upper extremity. This study will consist of a screening visit, an operative visit, and 9 post-operative follow-up visits at Week 4, and Months 3, 6, 9, 12, 15, 18, 21, and 24.

Studienübersicht

Detaillierte Beschreibung

This is a multicenter, 1:1 randomized, prospective, evaluator blinded, comparative study in participants requiring reconstruction of a mixed or motor nerve in the upper extremity. The study will assess recovery of motor and sensory function via MRCC score for nerve repairs with Avance Nerve Graft (Study Treatment) and sural nerve autograft (Comparator) through non-inferiority analyses. Participants will be considered enrolled to the study once all screening and eligibility criteria have been met and the participant has been centrally randomized to either Avance Nerve Graft or sural nerve autograft; Inclusion and exclusion criteria are defined at decision points for pre-operative screening eligibility and operative eligibility. This study will consist of a screening visit, an operative visit, and 9 post-operative follow-up visits at Week 4, and Months 3, 6, 9, 12, 15, 18, 21, and 24.

Studientyp

Interventionell

Einschreibung (Geschätzt)

178

Phase

  • Phase 4

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

    • Indiana
      • Indianapolis, Indiana, Vereinigte Staaten, 46260
        • Rekrutierung
        • OrthoIndy
        • Kontakt:
        • Hauptermittler:
          • Brandon Smetana, MD

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

Study Participant Criteria

  1. Be ≥ 18 years of age at the time of consent;
  2. Willing and able to comply with all aspects of the treatment and evaluation schedule over a 24-month duration;
  3. Provide documented Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent prior to initiation of any study procedures;

    Injury/Repair Criteria for Each Nerve

  4. Primary or secondary nerve injury repair with sural nerve autograft or Avance Nerve Graft for fully transected reconstruction of the following upper extremity mixed and/or motor nerve(s):

    • Median nerve: proximal nerve stump within 20 cm from the center point of the thenar eminence and distal to the crease of the elbow;
    • Anterior interosseous nerve;
    • Median nerve recurrent motor branch;
    • Radial nerve: proximal nerve stump within 20 cm of the center of the forearm (midpoint between the tip of the olecranon and the styloid process) and distal to the mid-humerus;
    • Posterior interosseous nerve.
  5. Zone of injury of eligible nerve(s) resectable to healthy nerve both distally and proximally and within the anatomical regions of Inclusion Criterion #4;
  6. In study participants with multiple eligible nerve repairs, repair of all eligible nerves completed with the same study treatment, either Avance Nerve Graft or sural nerve autograft;
  7. Measured nerve gap(s) following resection > 25 mm;
  8. Nerve(s) repaired ≤ 120 days post injury;
  9. Undergo coaptation on both the proximal and distal portion of the nerve gap(s) per the USPI for Avance Nerve Graft and per standard of care for sural nerve autograft; and
  10. Either treatment method, Avance Nerve Graft or sural nerve autograft, is a viable option for all eligible nerve repair(s) (i.e., volume of injured nerve[s] does not exceed availability of sural nerve autograft for reconstruction, study participants are not treated with a combination of treatment types).

Exclusion Criteria:

Study Participant Criteria

  1. Currently enrolled in another clinical study that may interfere with treatment, assessment of recovery, or participation in this study;
  2. Deformities or injuries of the limb, hand, or digits that affect both the primary and secondary assessments for eligible nerve repair(s);
  3. History of neuropathy of any etiology, diabetic neuropathy or any other known neuropathy including compressive/traumatic neuropathies affecting the target limb;
  4. History of progressive neurodegenerative or autoimmune disorder affecting peripheral nerve or motor function (e.g., amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease);
  5. History of chronic ischemic condition of the upper extremity;
  6. Expected use of medication during the study that is known to impact nerve regeneration or to cause peripheral neuropathy;
  7. Undergoing or expected to undergo treatment with chemotherapy, radiation therapy, or other known treatment which affects the growth of neural and/or vascular systems;
  8. Participant is unlikely to comply with all study requirements and standard medical care procedures for the duration of the study schedule;

    Injury/Repair Criteria for Each Nerve

  9. Median nerve repairs where the ulnar nerve has been transected due to injury or repair;
  10. Repair(s) of a sensory-only proximal nerve stump;
  11. Incomplete nerve transections;
  12. Multilevel nerve injury pattern requiring two or more isolated reconstructions along the nerve pathway (for example, reconstruction of median nerve in forearm and recurrent motor branch resulting in repair pattern of graft to native nerve to graft to distal target);
  13. Inadequate soft tissue coverage or extensive soft tissue injury which will impair recovery assessment;
  14. Nerve avulsion injuries and nerve traction injuries resulting in rupture of the nerve;
  15. Replantation/amputation of the limb, hand, or digits involved in both the primary and secondary assessments for eligible nerve repair(s);
  16. Nerve repairs utilizing either end-to-side or side-to-side coaptation techniques;
  17. Nerve transfer, tendon transfer, or other concomitant treatment at the time of nerve repair that affects assessment of function of the innervated muscle organ;
  18. Use of coaptation devices that include metallic components or activated polymers and coaptations completed with fibrin glue only; and
  19. Injuries with vascular damage resulting in inadequate perfusion despite repair (i.e., both radial and ulnar arteries injured [one injured artery is allowed]).

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Avance Nerve Graft
Study Treatment: Avance Nerve Graft repairs of mixed or motor nerves (> 25 mm gaps)
A commercially available, sterile, single-use peripheral nerve scaffold indicated for the treatment of functional deficits, manufactured from decellularized and sterilized extracellular matrix derived from human peripheral nerve tissue.
Andere Namen:
  • Acellular nerve allograft-arwx
Aktiver Komparator: Sural nerve autograft
Comparator: Sural nerve autograft repairs of mixed or motor nerves (> 25 mm gaps)
A patient's own peripheral nerve tissue harvested in a secondary surgical procedure of the lower extremity where a functioning sural nerve is sacrificed for use in the reconstruction of a nerve defect.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Recovery of motor function
Zeitfenster: Assessed at 24 months
Medical Research Council Classification (MRCC) of motor recovery score. This is an ordinal scale from M0-M5, with grade M0 meaning no contraction and M5 meaning full recovery in all muscles.
Assessed at 24 months
Recovery of sensory function
Zeitfenster: Assessed at 24 months
Medical Research Council Classification (MRCC) of sensory recovery score. This is an ordinal scale from S0-S4, with grade S0 meaning absence of sensibility in the autonomous area and S4 meaning complete recovery (2-point discrimination, 2-6 mm).
Assessed at 24 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Meaningful recovery (MR) of motor and sensory function
Zeitfenster: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Medical Research Council Classification (MRCC) of motor recovery score. Meaningful recovery is defined as ≥ M3 MRCC of motor recovery and ≥ S3 MRCC of sensory recovery.
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Treatment response (TR) of motor and sensory function
Zeitfenster: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Medical Research Council Classification (MRCC) of motor recovery score. Treatment response is defined as a 1-point increase in MRCC score from post-operative baseline.
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Time to MR of motor and sensory function
Zeitfenster: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Time from surgery to meaningful recovery of motor function in all repairs and of sensory function in mixed nerve repairs.
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Time to TR of motor and sensory function
Zeitfenster: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Time from surgery to treatment response of motor function in all repairs and of sensory function in mixed nerve repairs.
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
QuickDASH upper extremity disability score
Zeitfenster: Assessed at 24 months
The QuickDASH questionnaire (including Work and Sports/Performance Art modules if applicable) is a PROM questionnaire to measure physical functions and symptoms in participants with upper limb musculoskeletal disorders and will be used to assess the study participant's functional quality of life (QoL)as it pertains to the affected arm. This 11-item questionnaire addresses arm-specific symptoms and disability during the preceding week and is used to estimate the participant's view of disability. Each item is based on an ordinal scale from 1 to 5, where higher values are worse. QuickDASH scores range from 0 to 100, with a score of 0 indicating no disability and a score of 100 representing the most severe disability.
Assessed at 24 months
Lower Extremity Functional Scale (LEFS) score
Zeitfenster: Assessed at 24 months
The LEFS is a valid and reliable assessment for documenting function for individuals and groups with injury or disability to the lower extremity. It is based on the World Health Organization's model of disability and handicap and is applicable to a wide variety of participants with lower extremity orthopedic conditions, including participants with a range of disability levels, conditions, diseases, treatments, and ages. Applicable to sural nerve autograft group only. The LEFS consists of 20 questions, with each activity rated from 0 (extremely difficult or unable) to 4 (no difficulty). Scores range from 0 to 80, where higher scores indicate better lower limb function.
Assessed at 24 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: R. Glenn Gaston, MD, OrthoCarolina Research Institute, Inc.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

12. Juni 2026

Primärer Abschluss (Geschätzt)

5. Dezember 2030

Studienabschluss (Geschätzt)

5. Dezember 2030

Studienanmeldedaten

Zuerst eingereicht

15. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

15. Juni 2026

Zuerst gepostet (Tatsächlich)

18. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. Juni 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Periphere Nervenverletzung

Klinische Studien zur Avance Nerve Graft

Abonnieren